DCK and non-small cell lung carcinoma: Regarding NSCLC, Sève et al. assessed the protein abundance of cN-II, hENT1, the human concentrative nucleoside transporter-3 (hCNT3) and dCK by immunohistochemistry (IHC), in tumors of patients with locally or advanced disease, treated with gemcitabine, and correlated it with clinical outcome [23].